Bank of New York Mellon Corp Purchases Shares of 4,319 Pro-Dex, Inc. (NASDAQ:PDEX)

Bank of New York Mellon Corp acquired a new stake in Pro-Dex, Inc. (NASDAQ:PDEX) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 4,319 shares of the medical instruments supplier’s stock, valued at approximately $202,000. Bank of New York Mellon Corp owned about 0.13% of Pro-Dex at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after buying an additional 1,028 shares during the period. Ritholtz Wealth Management acquired a new stake in Pro-Dex during the 4th quarter worth approximately $572,000. JPMorgan Chase & Co. boosted its stake in Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after purchasing an additional 529 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after buying an additional 2,296 shares in the last quarter. 15.28% of the stock is owned by institutional investors.

Pro-Dex Stock Performance

Shares of NASDAQ:PDEX opened at $48.23 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. Pro-Dex, Inc. has a 1 year low of $16.84 and a 1 year high of $59.60. The stock has a market capitalization of $157.28 million, a price-to-earnings ratio of 24.00 and a beta of 0.68. The company’s 50 day simple moving average is $40.21 and its 200 day simple moving average is $39.99.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, research analysts predict that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Raymond E. Cabillot sold 5,381 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $41.64, for a total transaction of $224,064.84. Following the sale, the director now directly owns 319,752 shares in the company, valued at approximately $13,314,473.28. The trade was a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 47,475 shares of company stock valued at $2,186,594 in the last 90 days. Corporate insiders own 47.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Pro-Dex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.